Suchergebnisse - "Zhao, Hui"

PubPharm (81)

1

Auricular Vagal Nerve Stimulation Inhibited Central Nerve Growth Factor/Tropomyosin Receptor Kinase A/Phospholipase C-Gamma Signaling Pathway in Functional Dyspepsia Model Rats With Gastric Hypersensitivity

enthalten in: Neuromodulation : journal of the International Neuromodulation Society | 2024

von Zhou, J. | Chen, H. | Xu, W. | +4

2

Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema : a 12-month clinical trial

enthalten in: Frontiers in endocrinology | 2024

von Li, S. | Tao, Y. | Yang, M. | +4

3

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

enthalten in: Molecular carcinogenesis | 2024

von Liu, A. | Zhang, S. | Wang, M. | +14

4

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancer

enthalten in: Journal of cancer research and clinical oncology | 2023

von Xie, X. | Li, X. | Liu, G. | +3

5

Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC

enthalten in: European journal of medicinal chemistry | 2023

von Liu, B. | Gao, F. | Zhao, H. | +7

6

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2023

von Li, S. | Zhao, S. | Liang, N. | +13

7

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

8

Interim survival analysis of the randomized phase III GEMSTONE-302 trial : sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

enthalten in: Nature cancer | 2023

von Zhou, C. | Wang, Z. | Sun, M. | +31

ErratumIn: Nat Cancer. 2024 Jan 5;:. - PMID 38182915

9

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer : a pooled analysis from two phase 2 studies

enthalten in: BMC medicine | 2023

von Hu, X. | Zhang, S. | Ma, Z. | +27

10

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer : a phase Ib study

enthalten in: BMC cancer | 2023

von Hu, X. | Cui, X. | Wang, Z. | +16

1
2
3
4
5
6
7
8
9
Nächster »
[9]